Besides this, the therapeutic armamentarium for patients with IBD includes immunosuppressives, like purine analogues or methotrexate, and immunomodulators, like TNF inhibitors, and non-TNF-targeted biologics and targeted small-molecule therapies [22]. Here, TNF is linked to inflammatory bowel disease.